CAJ | 학술논문

目的：探讨RapidArc在前列腺癌放疗中的适用性。方法：对6例前列腺癌患者设计双弧RapidArc计划，处方剂量为7600cGy。用 COMPASS系统验证剂量。利用剂量体积直方图分析临床靶区、危及器官OARs的各评价指标。结果：CTV的HI、CI分别为1.08±0.03、0.87±0.06，有较好的均匀性和适合度。PTV的HI、CI稍差。膀胱和直肠的V40仅为（18.98±4.82）％和（20.50±3.03）％，平均剂量也较低，在3000cGy左右。股骨头D5％也在4000cGy以内。COMPASS剂量验证所得CTV和PTV各指标差异在4％以内，危及器官评价指标差异在5％以内。等中心处绝对剂量准确率达（99.08±0.66）％，靶区和各危及器官的γ通过率达96％、98％以上。结论：RapidArc能够满足前列腺癌放疗的临床剂量学要求。
목적：탐토RapidArc재전렬선암방료중적괄용성。방법：대6례전렬선암환자설계쌍호RapidArc계화，처방제량위7600cGy。용 COMPASS계통험증제량。이용제량체적직방도분석림상파구、위급기관OARs적각평개지표。결과：CTV적HI、CI분별위1.08±0.03、0.87±0.06，유교호적균균성화괄합도。PTV적HI、CI초차。방광화직장적V40부위（18.98±4.82）％화（20.50±3.03）％，평균제량야교저，재3000cGy좌우。고골두D5％야재4000cGy이내。COMPASS제량험증소득CTV화PTV각지표차이재4％이내，위급기관평개지표차이재5％이내。등중심처절대제량준학솔체（99.08±0.66）％，파구화각위급기관적γ통과솔체96％、98％이상。결론：RapidArc능구만족전렬선암방료적림상제량학요구。
Objective:To study the application suitability of RapidArc for prostate cancer. Methods:We design two arcs RapidArc plan for 6 patients. Prescription dose was 7600cGy. The COMPASS dose verification system was used to verify these plans. Target and organs at risk( OAR)were evaluated with dose-volume histograms( DVH). Results:CTV had good HI,CI,separately was 1. 08 ± 0. 03,0. 87 ± 0. 06. PTV HI,CI slightly worse. The V40 of blad-der and rectum were(18. 98 ± 4. 82)%,(20. 50 ± 3. 03)%. The Dmean was low,at about 3000cGy. The femoral head D5% within 4000cGy. The COMPASS dose verification of CTV and PTV index difference was less than 4%. In addi-tion,organs at risk evaluation index difference was less than 5%. Center absolute dose accuracy was(99. 08 ± 0. 66)%. The gamma pass rates of target and OARs were more than 96%,98%. Conclusion:RapidArc could satisfy the clinical requirements of dose radiotherapy for prostate cancer.